Compare Neurocrine Biosciences Inc (NBIX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Target Corporation — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while Target Corporation trades at $153.88 (market cap $70.31B). The key difference: Target Corporation is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and Target Corporation pays a 3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Target Corporation for 137 Days on average.
| NBIX | TGT | |
|---|---|---|
Market Cap | $14.36B | $70.31B |
Volume | 1,237,180 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $169.90 |
52-Week Low | $123.10 | $83.68 |
Typical Hold Time | 23 Days | 137 Days |
Enterprise Value | $14.37B | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Target (TGT) trades at $153.77, up 1.86% today, with a bearish technical signal but strong fundamental support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 estimate. Valuation ratios like a P/E of 16.05 and P/S of 0.65 appear attractive relative to historical averages. Recent news highlights strategic price cuts on 2,000 items to boost holiday sales and market share.
The outlook is cautiously optimistic, supported by solid profitability, dividend reliability, and analyst consensus pointing to upside. Key risks include competitive pressures, margin compression from pricing strategies, and broader retail sector volatility. The consensus price target of $167.18 suggests potential appreciation, but investors should weigh execution risks against growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
